French West Indies Leptospirosis Study (LEPTO)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Leptospirosis is a zoonosis of worldwide distribution whose incidence is higher in the tropics, where conditions for transmissions are favorable. The disease is endemic in Martinique and Guadeloupe, two Caribbean islands of the French West Indies. In tropical areas, many wild and domestic animals serve as reservoirs for pathogenic Leptospira strains and contaminate the environment by shedding the organisms in their urine. Humans are usually infected through abraded skin or mucous membrane contact with water contaminated by the urine of animal reservoirs, and less frequently by direct contact with animals or their urine. The mean incubation period is 10 days, with a usual range of 2-20 days. Clinical manifestations are protean and the spectrum of symptoms range from subclinical or mild anicteric febrile illness to acute renal failure and respiratory distress syndrome which are associated with high mortality rates.
The microscopic agglutination test (MAT) and culture are the reference standard test for diagnosis of leptospirosis, but they are only available in reference laboratories and their conclusive results requires convalescent sample or prolonged incubation. At present, only direct detection methods using PCR might provide rapid diagnosis during the early acute stage of the illness, when treatment is likely to have the greatest benefit.
Quantitative PCR also offers the ability to measure level of leptospiremia in clinical samples. Using qPCR based diagnosis, the investigators have the opportunity to study the association of level of leptospiremia and clinical manifestations in French West Indies. All qPCR-positive samples will be used for molecular typing.
| Condition |
|---|
| Leptospirosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Utility of Quantitative Polymerase Chain Reaction to Predict Clinical Outcome of Leptospirosis in French West Indies |
- Complicated forms of leptospirosis [ Time Frame: 12 weeks ]Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.
- quality of life [ Time Frame: 12 weeks ]Changes in quality of life, measured with the EuroQol® questionnaire in the first 3 weeks and 12 weeks after the onset of dengue fever symptoms.
Biospecimen Retention: Samples With DNA
| Estimated Enrollment: | 150 |
| Study Start Date: | December 2010 |
| Estimated Study Completion Date: | December 2016 |
| Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
Principal objective
To determine if leptospiral bacterial load is associated with severe evolution of the disease (organ failure, internal bleeding, death) in French West Indies.
Secondary objective
- To identify demographic, clinical, biological, bacteriological, and genetic factors (HLA) associated with severe complications of leptospirosis (organ failure, internal bleeding, death).
- To identify demographic, clinical, biological, bacteriological, and genetic factors (HLA) associated with an altered quality of life after the acute phase of leptospirosis.
- To collect human biological samples to allow studies of the individual susceptibility to the infection (genetic polymorphisms, HLA).
Eligibility| Ages Eligible for Study: | 18 Years to 120 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adults (more than 18 years)
- Consulting a participating hospital center (emergency room, full hospitalization, day hospitalization, or outpatient visit).
- Diagnosis of leptospirosis confirmed by qPCR
- Possibility of follow-up throughout the 12-week study period.
- Patient registered in the French medical social security national program
- Acceptance to participate in the study and in follow-up; informed consent of the patient or a legal representative (patients unable to sign the consent form).
Exclusion Criteria:
- Negativity of leptospirosis qPCR based diagnosis
- Children under 18 years old
- No possible follow-up after the first visit
- Refusal to participate in the study
- Patient not registered in the French medical social security national program
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01607047
| Contact: Patrick Hochedez, MD | 596 55 23 01 ext 00596 | patrick.hochedez@chu-fortdefrance.fr |
| France | |
| CHU Pointe-à-Pitre Abymes | Recruiting |
| Pointe-à-Pitre, Guadeloupe, France, 972 | |
| Contact: Isabelle Lamaury, MD 5 90 89 15 45 ext 00590 | |
| CHU Martinique | Recruiting |
| Fort de France, Martinique, France, 97261 | |
| Contact: Patrick Hochedez, MD 596 55 23 01 ext 00596 patrick.hochedez@chu-fortdefrance.fr | |
| Principal Investigator: Patrick Hochedez, MD | |
| Principal Investigator: | Patrick Hochedez, MD | CHU fort de france |
More Information
| Responsible Party: | University Hospital Center of Martinique |
| ClinicalTrials.gov Identifier: | NCT01607047 History of Changes |
| Other Study ID Numbers: |
CHU FDF 10/B/13 |
| Study First Received: | May 24, 2012 |
| Last Updated: | February 29, 2016 |
Keywords provided by University Hospital Center of Martinique:
|
leptospirosis qPCR cohort french west indies |
blood sample collection pronostic diagnosis |
Additional relevant MeSH terms:
|
Leptospirosis Weil Disease Gram-Negative Bacterial Infections Bacterial Infections Spirochaetales Infections |
ClinicalTrials.gov processed this record on July 14, 2017


IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
